Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society

Molecular syndromology

article

Hamlett, Eric D.¹  Flores-Aguilar, Lisi²  Handen, Benjamin⁴  Potier, Marie-Claude⁵  Granholm, Ann-Charlotte⁶  Sherman, Stephanie⁷  Puig, Victoria⁸  Santoro, Jonathan D.⁹  Carmona-Iragui, María^1,10  Rebillat, Anne-Sophie^1,11  Head, Elizabeth³  Strydom, André^1,12  Busciglio, Jorge^1,13 

[1]Department of Pathology and Laboratory Medicine, Medical University of South Carolina

[2]Department of Anatomy and Cell Biology, McGill University

[3]Department of Pathology and Laboratory Medicine, University of California

[4]Department of Psychiatry, University of Pittsburgh

[5]Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital

[6]Department of Neurosurgery, University of Colorado Anschutz Medical Campus

[7]Department of Human Genetics, Emory University

[8]Catalan Institute of Nanoscience and Nanotechnology

[9]Neurological Institute, University of Southern California Keck School of Medicine

[10]Hospital de la Santa Crue I Sant Pau, Universitat Autònoma de Barcelona

[11]Institut Jérôme Lejeune

[12]Institute of Psychiatry, King’s College London

[13]Neurobiology and Behavior School of Biological Sciences, University of California

关键词: Down syndrome;    Intellectual disability;    Clinical research;    Preclinical research;    Biomarkers;   

DOI  :  10.1159/000526021

学科分类：基础医学

来源: S Karger AG

【 摘 要 】

Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8–10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer’s disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21.

【 授权许可】

CC BY